Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2021 - Issue
Submit an article Journal homepage
118
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

Claus F Vogelmeier1 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, GermanyCorrespondence[email protected]
View further author information
,
Ian P Naya2 Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK;3 RAMAX Ltd, Bramhall, Cheshire, UKView further author information
,
François Maltais4 Centre De Pneumologie, Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Université Laval, Québec, CanadaORCID Iconhttps://orcid.org/0000-0002-6809-4651View further author information
ORCID Icon,
Leif Bjermer5 Respiratory Medicine and Allergology, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0002-3441-8099View further author information
ORCID Icon,
Edward M Kerwin6 Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USAORCID Iconhttps://orcid.org/0000-0002-1697-9036View further author information
ORCID Icon,
Lee Tombs7 Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UKView further author information
,
Paul W Jones2 Global Specialty & Primary Care, GSK, Brentford, Middlesex, UKORCID Iconhttps://orcid.org/0000-0001-6087-9182View further author information
ORCID Icon,
Chris Compton2 Global Specialty & Primary Care, GSK, Brentford, Middlesex, UKView further author information
,
David A Lipson8 Respiratory Clinical Sciences, GSK, Collegeville, PA, USA;9 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0001-6732-4593View further author information
ORCID Icon &
Isabelle H Boucot2 Global Specialty & Primary Care, GSK, Brentford, Middlesex, UK;10 Medical Emerging Markets, GSK, Brentford, Middlesex, UKORCID Iconhttps://orcid.org/0000-0003-0410-4969View further author information
ORCID Icon show all
Pages 1215-1226 | Published online: 03 May 2021

References

  • Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD.S27480
  • Sun Y, Zhou J. New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019;14:1119–1125. doi:10.2147/COPD.S205382
  • Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2689–2697. doi:10.1056/NEJMra030415
  • Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178. doi:10.1016/s0140-6736(09)61298-8
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Accessed January 2021.
  • Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a Pooled Analysis of Three Randomized Trials. Adv Ther. 2017;33(12):2188–2199. doi:10.1007/s12325-016-0430-6
  • Naya IP, Tombs L, Lipson DA, Compton C. Preventing clinically important deterioration of COPD with addition of umeclidinium to inhaled corticosteroid/long-acting beta2-agonist therapy: an integrated post hoc analysis. Adv Ther. 2018;35(10):1626–1638. doi:10.1007/s12325-018-0771-4
  • Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/copd.s101612
  • Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi:10.2147/copd.s133307
  • D’Urzo A, Bader G, Shen S, Goyal P, Altman P. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. NPJ Prim Care Respir Med. 2018;28(1):18. doi:10.1038/s41533-018-0084-8
  • Singh D, D’Urzo AD, Chuecos F, Muñoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-0
  • Kostikas K, Mackay AJ, Vogelmeier CF, et al. Early Clinically Important Improvement (ECII) and exacerbation outcomes in COPD patients. Int J Chron Obstruct Pulmon Dis. 2020;15:1831–1838. doi:10.1183/13993003.congress-2018.OA1657
  • Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
  • Donohue JF. Minimal clinically important differences in COPD lung function. Int J Chron Obstruct Pulmon Dis. 2005;2(1):111–124. doi:10.1081/copd-200053377
  • Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. Copd. 2005;2(1):99–103. doi:10.1081/copd-200050666
  • Leidy NK, Murray LT, Monz BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15(1):124. doi:10.1186/s12931-014-0124-z
  • Jones PW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/copd-200050513
  • Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/s2213-2600(14)70001-3
  • Miravitlles M, Worth H, Soler-Cataluña JJ, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an Observational Study (ASSESS). Int J Chron Obstruct Pulmon Dis. 2016;13(5):561–568. doi:10.3109/15412555.2016.1150447
  • Calverley PM, Tetzlaff K, Dusser D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391–3405. doi:10.2147/copd.s145814
  • Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873–884. doi:10.1183/09031936.00025214
  • Kostikas K, Greulich T, Mackay AJ, et al. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res. 2019;5(1):00243–2018. doi:10.1183/23120541.00243-2018

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.